Aerie Pharmaceuticals Inc (AERI) 34.42 $AERI
Aerie Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference
Business Wire - Wed Apr 08, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015 at 12:50p.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
AERI: 34.42 (-0.70)
Aerie Pharma: Finding Value In The Ophthalmic Space
Mark Chapman - at Seeking Alpha - Fri Apr 03, 8:31AM CDT
AERI: 34.42 (-0.70)
Aerie Pharma completes enrollment in Phase 3 Rhopressa study
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 6:52AM CDT
AERI: 34.42 (-0.70)
Aerie Pharmaceuticals Completes Enrollment in Second Phase 3 Registration Trial ("Rocket 2"
of Rhopressa(TM), Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma
Business Wire - Tue Mar 24, 5:00AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the completion of enrollment in the Company's second Phase 3 registration trial ("Rocket 2" of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Rocket 2 will measure efficacy over three months, as well as safety over one year. The primary efficacy endpoint of the trial is to demonstrate non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol. Timolol is the most widely used comparator in registration trials for glaucoma. The Company's Phase 3 program also includes "Rocket 1," a 90-day efficacy registration trial for which data are expected mid-second quarter 2015, and "Rocket 3," a one-year, safety-only registration trial in Canada. Pending successful results from the Phase 3 registration studies, the Company expects to submit a New Drug Application filing by mid-2016.
AERI: 34.42 (-0.70)
Inotek: Tepid IPO Only Postpones Existential Threat And Significantly Delays Product Launch
Northern Fundamentals - at Seeking Alpha - Fri Mar 13, 4:00AM CDT
ITEK: 4.80 (-0.02), AERI: 34.42 (-0.70)
Aerie Pharmaceuticals to Participate in Two Investor Conferences in March
Business Wire - Tue Mar 03, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present an overview of the company at the following conferences in March.
AERI: 34.42 (-0.70)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 2.12 (+0.17), AGN: 240.22 (+2.88), ACAD: 38.55 (-0.20), ITEK: 4.80 (-0.02), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), FOMX: 10.94 (-0.02), AERI: 34.42 (-0.70), CBMG: 32.14 (+2.21)
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 8:58PM CST
AERI: 34.42 (-0.70)
Aerie reports 4Q loss
Automated Insights - Mon Mar 02, 4:16PM CST
BEDMINSTER, N.J. (AP) _ Aerie Pharmaceuticals Inc. (AERI) on Monday reported a loss of $16.5 million in its fourth quarter.
AERI: 34.42 (-0.70)
Aerie Pharmaceuticals misses by $0.12
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:27PM CST
AERI: 34.42 (-0.70)
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business and Product Development Update
Business Wire - Mon Mar 02, 3:01PM CST
--Conference Call and Webcast Today, March 2, at 5:00 p.m. ET
AERI: 34.42 (-0.70)
4 Stocks Breaking Out on Big Volume: Zillow, Aerie and More
at The Street - Wed Feb 18, 12:14PM CST
These stocks rising on unusual volume are within range of triggering breakout trades.
ARRS: 30.54 (+0.38), AERI: 34.42 (-0.70), Z: 99.00 (+1.96), SIEN: 16.45 (-0.22)
Aerie Pharmaceuticals Announces Potential Breakthroughs with New Preclinical Research
Business Wire - Wed Feb 18, 5:00AM CST
--Early-Stage Aerie-Owned Product Candidate, AR-13154, Shows Potential to Treat Age-Related Macular Degeneration
AERI: 34.42 (-0.70)
Aerie Pharmaceuticals Announces Rhopressa(TM) Presentation at 2015 Meeting of the Association for Ocular Pharmacology and Therapeutics
Business Wire - Tue Feb 17, 3:05PM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Casey C. Kopczynski, Ph.D., Aerie's Chief Scientific Officer, will provide an overview on Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension, at the 2015 Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT), which will be held in Charleston, S.C., February 26 through March 1, 2015.
AERI: 34.42 (-0.70)
Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2014 Financial Results and Host Conference Call on Monday, March 2, 2015
Business Wire - Tue Feb 17, 6:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its fourth quarter and year end 2014 financial results will be released after the market closes on Monday, March 2, 2015. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
AERI: 34.42 (-0.70)
Aerie Pharmaceuticals Is Speeding Towards Improving The Management Of Glaucoma
Prohost Biotech - Seeking Alpha - Thu Feb 12, 1:10PM CST
Aerie Pharmaceuticals (NASDAQ: AERI ) is a development-stage pharmaceutical Company focused on eye diseases, mainly glaucoma. The firm's lead product candidate, Rhopressa, is a once-daily triple-action eye drop that demonstrated ability to lower...
AERI: 34.42 (-0.70)
Recent Developments at Pharma Companies: Special Research on Aerie Pharmaceuticals, AEterna Zentaris, Affimed, Agenus, and Agile Therapeutics
PR Newswire - Tue Feb 03, 7:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Aerie Pharmaceuticals (NASDAQ: AERI), AEterna Zentaris (NASDAQ: AEZS), Affimed (NASDAQ: AFMD), Agenus (NASDAQ: AGEN), and Agile Therapeutics (NASDAQ: AGRX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AGEN: 6.08 (+0.21), AGRX: 12.25 (+0.17), AFMD: 7.94 (+0.11), AEZS: 0.60 (-0.03), AERI: 34.42 (-0.70)
Aerie Pharmaceuticals to Participate in Two Investor Conferences in February
Business Wire - Tue Feb 03, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that company management will present an overview of the company at the following conferences in February.
AERI: 34.42 (-0.70)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 7.24 (+0.09), ITEK: 4.80 (-0.02), NBS: 2.88 (+0.06), FOMX: 10.94 (-0.02), AERI: 34.42 (-0.70), OCUL: 25.90 (-0.05), AGN: 240.22 (+2.88), CANF: 2.12 (+0.17), ACAD: 38.55 (-0.20), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), TEVA: 63.01 (-1.15), OHRP: 2.72 (+0.08), CBMG: 32.14 (+2.21)
Commit To Buy Aerie Pharmaceuticals At $25, Earn 20.9% Annualized Using Options
at The Street - Tue Jan 13, 10:40AM CST
Investors considering a purchase of Aerie Pharmaceuticals Inc stock, but cautious about paying the going market price of $29.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
AERI: 34.42 (-0.70)
Aerie Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference
Business Wire - Wed Apr 08, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015 at 12:50p.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
AERI: 34.42 (-0.70)
Aerie Pharma: Finding Value In The Ophthalmic Space
Mark Chapman - at Seeking Alpha - Fri Apr 03, 8:31AM CDT
AERI: 34.42 (-0.70)
Aerie Pharma completes enrollment in Phase 3 Rhopressa study
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 6:52AM CDT
AERI: 34.42 (-0.70)
Aerie Pharmaceuticals Completes Enrollment in Second Phase 3 Registration Trial ("Rocket 2"
of Rhopressa(TM), Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma Business Wire - Tue Mar 24, 5:00AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the completion of enrollment in the Company's second Phase 3 registration trial ("Rocket 2"
of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Rocket 2 will measure efficacy over three months, as well as safety over one year. The primary efficacy endpoint of the trial is to demonstrate non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol. Timolol is the most widely used comparator in registration trials for glaucoma. The Company's Phase 3 program also includes "Rocket 1," a 90-day efficacy registration trial for which data are expected mid-second quarter 2015, and "Rocket 3," a one-year, safety-only registration trial in Canada. Pending successful results from the Phase 3 registration studies, the Company expects to submit a New Drug Application filing by mid-2016. AERI: 34.42 (-0.70)
Inotek: Tepid IPO Only Postpones Existential Threat And Significantly Delays Product Launch
Northern Fundamentals - at Seeking Alpha - Fri Mar 13, 4:00AM CDT
ITEK: 4.80 (-0.02), AERI: 34.42 (-0.70)
Aerie Pharmaceuticals to Participate in Two Investor Conferences in March
Business Wire - Tue Mar 03, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present an overview of the company at the following conferences in March.
AERI: 34.42 (-0.70)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 2.12 (+0.17), AGN: 240.22 (+2.88), ACAD: 38.55 (-0.20), ITEK: 4.80 (-0.02), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), FOMX: 10.94 (-0.02), AERI: 34.42 (-0.70), CBMG: 32.14 (+2.21)
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 8:58PM CST
AERI: 34.42 (-0.70)
Aerie reports 4Q loss
Automated Insights - Mon Mar 02, 4:16PM CST
BEDMINSTER, N.J. (AP) _ Aerie Pharmaceuticals Inc. (AERI) on Monday reported a loss of $16.5 million in its fourth quarter.
AERI: 34.42 (-0.70)
Aerie Pharmaceuticals misses by $0.12
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:27PM CST
AERI: 34.42 (-0.70)
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business and Product Development Update
Business Wire - Mon Mar 02, 3:01PM CST
--Conference Call and Webcast Today, March 2, at 5:00 p.m. ET
AERI: 34.42 (-0.70)
4 Stocks Breaking Out on Big Volume: Zillow, Aerie and More
at The Street - Wed Feb 18, 12:14PM CST
These stocks rising on unusual volume are within range of triggering breakout trades.
ARRS: 30.54 (+0.38), AERI: 34.42 (-0.70), Z: 99.00 (+1.96), SIEN: 16.45 (-0.22)
Aerie Pharmaceuticals Announces Potential Breakthroughs with New Preclinical Research
Business Wire - Wed Feb 18, 5:00AM CST
--Early-Stage Aerie-Owned Product Candidate, AR-13154, Shows Potential to Treat Age-Related Macular Degeneration
AERI: 34.42 (-0.70)
Aerie Pharmaceuticals Announces Rhopressa(TM) Presentation at 2015 Meeting of the Association for Ocular Pharmacology and Therapeutics
Business Wire - Tue Feb 17, 3:05PM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Casey C. Kopczynski, Ph.D., Aerie's Chief Scientific Officer, will provide an overview on Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension, at the 2015 Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT), which will be held in Charleston, S.C., February 26 through March 1, 2015.
AERI: 34.42 (-0.70)
Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2014 Financial Results and Host Conference Call on Monday, March 2, 2015
Business Wire - Tue Feb 17, 6:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its fourth quarter and year end 2014 financial results will be released after the market closes on Monday, March 2, 2015. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
AERI: 34.42 (-0.70)
Aerie Pharmaceuticals Is Speeding Towards Improving The Management Of Glaucoma
Prohost Biotech - Seeking Alpha - Thu Feb 12, 1:10PM CST
Aerie Pharmaceuticals (NASDAQ: AERI ) is a development-stage pharmaceutical Company focused on eye diseases, mainly glaucoma. The firm's lead product candidate, Rhopressa, is a once-daily triple-action eye drop that demonstrated ability to lower...
AERI: 34.42 (-0.70)
Recent Developments at Pharma Companies: Special Research on Aerie Pharmaceuticals, AEterna Zentaris, Affimed, Agenus, and Agile Therapeutics
PR Newswire - Tue Feb 03, 7:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Aerie Pharmaceuticals (NASDAQ: AERI), AEterna Zentaris (NASDAQ: AEZS), Affimed (NASDAQ: AFMD), Agenus (NASDAQ: AGEN), and Agile Therapeutics (NASDAQ: AGRX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AGEN: 6.08 (+0.21), AGRX: 12.25 (+0.17), AFMD: 7.94 (+0.11), AEZS: 0.60 (-0.03), AERI: 34.42 (-0.70)
Aerie Pharmaceuticals to Participate in Two Investor Conferences in February
Business Wire - Tue Feb 03, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that company management will present an overview of the company at the following conferences in February.
AERI: 34.42 (-0.70)
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 7.24 (+0.09), ITEK: 4.80 (-0.02), NBS: 2.88 (+0.06), FOMX: 10.94 (-0.02), AERI: 34.42 (-0.70), OCUL: 25.90 (-0.05), AGN: 240.22 (+2.88), CANF: 2.12 (+0.17), ACAD: 38.55 (-0.20), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), TEVA: 63.01 (-1.15), OHRP: 2.72 (+0.08), CBMG: 32.14 (+2.21)
Commit To Buy Aerie Pharmaceuticals At $25, Earn 20.9% Annualized Using Options
at The Street - Tue Jan 13, 10:40AM CST
Investors considering a purchase of Aerie Pharmaceuticals Inc stock, but cautious about paying the going market price of $29.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
AERI: 34.42 (-0.70)
